LEXINGTON, KY - The Chairman of the Board of Directors of the Association of Racing Commissioners International (ARCI) announced today that a new committee will be formed to work with individual commissions to complete the implementation of the ARCI medication reforms. The reforms are embodied in the Model Rules, the association’s recommended best regulatory practices and policies.
Mark Lamberth, who also serves as a commissioner on the Arkansas State Racing Commission, made the announcement following a Monday conference call with racing regulators. The regulators asked to participate will be named in the near future.
The goal of the committee is to complete implementation of medication reforms that were developed by ARCI members and staff working with the Racing Medication and Testing Consortium (RMTC). The committee will identify the jurisdictions that have yet to adopt portions of the reforms and develop strategies to work with the individual commission to advance the reforms.
“Racing regulators working together with the racing industry have made tremendous strides over the past few years in some of the biggest racing states to implement sound, uniform medication policies in areas such as therapeutic medication use, laboratory testing standards and accreditation, and increased penalties for repeat offenders. There are some jurisdictions that have not implemented all of these reforms, and the goal of the committee is to aid those jurisdictions in the implementation process,” said Lamberth.
Lamberth said that all racing regulators were uniform in prohibiting performance enhancing drugs, and the ARCI is committed to resolving relatively minor differences in regulations pertaining to testing thresholds for some therapeutic medications. “Full adoption of the ARCI Model Rules, which have been thoughtfully and carefully developed in conjunction with the RMTC, would accomplish that,” he said.
Lamberth also said that a model Request for Proposals for laboratory services was an important reform and predicted that racing commissions will rely upon it as laboratory contracts expire and future procurements are implemented.
“We know that the racing industry is in a much better position today than it was just five years ago when it comes to medication policy, and the regulators on this committee want to continue that progress for the good of racing,” added Lamberth.
Lamberth said that the committee will begin work immediately and report to the ARCI Board of Directors in December.